Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Quarterly results
CC transcript
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2023 Results – First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance –"
11/02/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Charles River Laboratories Announces Second-Quarter 2022 Results – Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance –"
05/04/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2021 Results – Third-Quarter Revenue of $895.9 Million – – Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 – – Updates 2021 Guidance –"
08/04/2021 8-K Quarterly results
Docs: "Charles River Laboratories Announces Second-Quarter 2021 Results Second-Quarter Revenue of $914.6 Million Second-Quarter GAAP Earnings per Share of $1.72 and Non-GAAP Earnings per Share of $2.61 Increases 2021 Guidance"
10/29/2020 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2020 Results – Third-Quarter Revenue of $743.3 Million – – Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 – – Increases 2020 Guidance –"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
07/31/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2019 Results – First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 – – Reaffirms 2019 Guidance Including Citoxlab –"
11/07/2018 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2018 Results – Third-Quarter Revenue of $585.3 Million – – Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 – – Updates 2018 Guidance –"
08/08/2018 8-K Quarterly results
Docs: "Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations – Second-Quarter Revenue of $585.3 Million – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 – – Increases 2018 Revenue Growth and Earnings per Share Guidance –"
05/10/2018 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations – First-Quarter Revenue of $494.0 Million – – First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $1.38 – – Updates 2018 Guidance –"
11/09/2017 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations – Third-Quarter Revenue of $464.2 Million – – Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 – – Updates 2017 Guidance –"
08/09/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
11/02/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
11/04/2015 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2015 Results from Continuing Operations – Third-Quarter Revenue of $349.5 Million – – Third-Quarter GAAP Earnings per Share of $0.79 and Non-GAAP Earnings per Share of $1.03 – – Updates 2015 Guidance –"
07/30/2015 8-K Quarterly results
Docs: "Charles River Laboratories Announces Second-Quarter 2015 Results from Continuing Operations – Second-Quarter Revenue of $339.6 Million – – Second-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $0.96 – – Updates 2015 Guidance for Celsis Acquisition – – Renews Strategic Partnership with AstraZeneca – – Plans to Reopen Shrewsbury, Massachusetts Facility in Early 2016 –"
04/29/2015 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2015 Results from Continuing Operations – First-Quarter Revenue of $320.4 Million – – First-Quarter GAAP Earnings per Share of $0.66 and Non-GAAP Earnings per Share of $0.79 – – Raises 2015 Constant-Currency Revenue Growth Guidance – – Reaffirms 2015 Reported Revenue Growth and Earnings per Share Guidance –"
10/29/2014 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations – Third-Quarter Revenue of $327.6 Million – – Third-Quarter GAAP Earnings per Share of $0.68 and Non-GAAP Earnings per Share of $0.86 – – Updates EPS Guidance for 2014 – – Acquires ChanTest Corporation – – Announces Management Promotions –"
08/06/2014 8-K Quarterly results
Docs: "Charles River Laboratories Announces Second-Quarter 2014 Results from Continuing Operations – Second-Quarter Revenue of $341.2 Million – – Second-Quarter GAAP Earnings per Share of $0.75 and Non-GAAP Earnings per Share of $0.97 – – Updates EPS Guidance for 2014 – – Revises Financial Reporting into Three Segments –"
04/30/2014 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2014 Results from Continuing Operations – First-Quarter Sales of $299.4 Million – – First-Quarter GAAP Earnings per Share of $0.67 and Non-GAAP Earnings per Share of $0.82 – – Raises Sales and Non-GAAP EPS Guidance for 2014; Reduces 2014 GAAP EPS Guidance –"
10/29/2013 8-K Quarterly results
Docs: "Charles River Laboratories Announces Third-Quarter 2013 Results from Continuing Operations – Third-Quarter GAAP Sales of $292.1 Million – – Third-Quarter GAAP Earnings per Share of $0.64 and Non-GAAP Earnings per Share of $0.79 – – Updates Sales and EPS Guidance for 2013 –"
07/31/2013 8-K Form 8-K - Current report
05/01/2013 8-K Quarterly results
Docs: "Charles River Laboratories Announces First-Quarter 2013 Results from Continuing Operations – First-Quarter Sales of $291.2 Million – – First-Quarter GAAP Earnings per Share of $0.53 and Non-GAAP Earnings per Share of $0.69 – – Updates 2013 Sales Guidance; Reaffirms 2013 EPS Guidance –"
10/30/2012 8-K Form 8-K - Current report
08/07/2012 8-K Form 8-K - Current report
05/02/2012 8-K Quarterly results
Docs: "Charles River Announces First-Quarter 2012 Results from Continuing Operations – First-Quarter Sales of $286.0 Million – – RMS Sales Increase 5.6%, and 6.5% in Constant Currency – – First-Quarter GAAP Earnings per Share of $0.54 and Non-GAAP Earnings per Share of $0.70 – – Reaffirms Sales and EPS Guidance for 2012 –"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy